Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis: A nationwide cohort study from the DANBIO and DERMBIO registries
Seminars in Arthritis and Rheumatism Feb 15, 2022
In this study, varying treatment responses to drugs with various types of action across rheumatoid arthritis (RA), axial spondyloarthritis (AxSpA), psoriatic arthritis (PsA) and psoriasis highlight the requirement for an individualized treatment approach, that considers the underlying disease, patient profile, and treatment history, despite the fact that these disease conditions have many overlaps in their pathogenesis.
In this nationwide cohort study using the prospective nationwide registries DANBIO and DERMBIO, researchers assessed the real-life drug survival of biologics and novel small-molecule therapies across various disease conditions such as RA, AxSpA, PsA, and psoriasis.
Participants were 12,089 patients (17,903 treatment series) in total, including 5,104 RA patients (7,867 series), 2,157 AxSpA patients (3,016 series3), 2,551 PsA patients (3,313 series), and 2,577 psoriasis patients (3,707 series).
In RA, highest drug survival was evident for rituximab followed by baricitinib, etanercept and tocilizumab respectively, in confounder-adjusted models.
In AxSpA, drug survival was shown to be high for golimumab than all other drugs, followed by secukinumab and etanercept and was lowest for infliximab.
Drug survival in PsA was the lowest for tofacitinib and infliximab relative to all other drugs.
Almost equally good performance was displayed by all other drugs, with a tendency of a generally higher drug survival for golimumab, followed by secukinumab and ixekizumab.
Guselkumab had the highest drug survival in psoriasis.
Exclusive Write-ups & Webinars by KOLs
Daily Quiz by specialty
Paid Market Research Surveys
Case discussions, News & Journals' summaries